(RTTNews) - H. Lundbeck A/S (HLBBF) announced headline results from the Phase IV THRIVE trial evaluating eptinezumab, an investigational humanised monoclonal antibody administered intravenously, in adults with migraine who had an inadequate response to one prior CGRP-targeting pr
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.